RILIMOGENE GALVACIREPVEC
UNII 59WJ3TGA5K

Substance Identification & Data

This profile provides standardized clinical and technical data for Rilimogene Galvacirepvec, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 59WJ3TGA5K.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1225283-43-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

59WJ3TGA5K

CAS Registry Number

1225283-43-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

RILIMOGENE GALVACIREPVEC

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C38681

National Cancer Institute reference terminology for clinical and research data.

INN ID

9622

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

YY-131

Identifier assigned by the United States Adopted Names Council.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Rilimogene Galvacirepvec. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

RILIMOGENE GALVACIREPVEC

Common Names & Synonyms

RECOMBINANT REPLICATING VACCINIA VIRAL VECTOR EXPRESSING A MODIFIED PROSTATE SPECIFIC ANTIGEN (PSA) PLUS THREE CO-STIMULATORY MOLECULES, LYMPHOCYTE ASSOCIATED FUNCTION ANTIGEN-3 (LFA-3), INTRACELLULAR ADHESION MOLECULE-1 (ICAM-1) AND B7.1

RILIMOGENE GALVACIREPVEC [INN]

RILIMOGENE GALVACIREPVEC [USAN]

RILIMOGENE GALVACIREPVEC [WHO-DD]